Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is there any estimation on revenue of TLC-2000 in USA / CANADA?
Wouldn't be surprised, if we close red today. I'm sure some of the seller used those prices to sell with less loss.
Greate news. Time to lunch T2000 and make some money.
Hey walterc,
if you have information, they make you that optimistic, please share.
They cant be confidential or business critical, otherwise you would not be allowed to know them.
Or is it just a gut instinct?
JA, true.
Ich stimme dir komplett zu.
Sie hätten ja nicht überschnell ihre deadlines abgeben müssen. Keine hat sie gezwungen, die deadlines to eng zu legen. Und sie dann zwei mal zu verschieben, um jeweils 3- 6 monate, ist schon ein grober vertrauensverlust.
Zuerst hieß es September, dann Dezember / Januar, nun ist es wohl März - Mai. Wer kann uns garantieren, dass es nicht erneut um 6 Monate auf November / Dezember 2016 verlegt wird, zusätzlich mit einer verschiebung des produktionsstarts von 2018 auf 2020 oder 2021?
Meiner meinung nach kompletter vertrauensverlust in allen bereichen.
PEA hat das ganze eingeläutet und FS führt es wohl weiter. Mal sehen ob wir in der zwischenzeit PEA3 / PEA4 und PEA5 sehen, mit IRR von 200% oder 500% :D. Lächerlich.
I just can say, he burns his own money as well.
He has more to lose then anybody here.
So its ok for me to lose my money if he loses his!
Hi Advo,
maybe they can work till the end without money. It will be the same, if they try to rise money under this circumstances :D. Lol
Theralase's anti-cancer research published in journal
2015-10-27 07:06 ET - News Release
Mr. Michael Borovec reports
THERALASE ANTI-CANCER TECHNOLOGY RESEARCH PUBLISHED IN INTERNATIONAL JOURNAL
Theralase Technologies Inc.'s latest anti-cancer technology research, combining photo dynamic compounds (PDC) with a naturally occurring glycoprotein, transferrin, and activating the combination with a specific wavelength of light, has been published in Photodiagnosis and Photodynamic Therapy. Photodiagnosis and Photodynamic Therapy is an international journal focused on the dissemination of scientific knowledge and clinical developments pertaining to the use of light and PDCs in the diagnosis and treatment of numerous medical conditions, across all medical specialties. Photodynamic therapy ("PDT") uses the combination of a PDC and a specific wavelength of light to produce cell-killing molecules, such as Reactive Oxygen Species ("ROS") to destroy the intended cellular target, thus proving to be a promising avenue for non-invasive cancer treatment. The novel Theralase PDC, TLD-1433, has previously shown efficacy in the destruction of microbial and cancerous tumours during preclinical in-vivo (animal) and in-vitro (cellular) studies. In Theralase's latest research, the binding of TLD-1433 with a naturally occurring glycoprotein, transferrin, results in further enhancements of TLD-1433's properties as an effective anti-cancer agent. When TLD-1433 is bound to transferrin, the combination results in: Increased: absorption in the green light spectrum (greater efficacy for superficial tumours) Increased absorption in the red and near infrared light spectrum (greater efficacy for deeper set tumours) Increased bleaching resistance (minimal loss in potency over time) Increased ROS production (increased efficacy) Reduced dark toxicity (no effect until light activated) Increased PDT mediated cell kill (increased efficacy) Increased tumour free survival time of mice compared to TLD1433 alone at identical light doses (enhanced efficacy) Roger Dumoulin-White, President and CEO, Theralase stated that, "The acceptance of Theralase's latest research for publication in a well-regarded international journal underlines the importance that the scientific community places on this cutting-edge technology. The TLC-3000 anti-cancer technology is on track to commence enrolling patients in late 4Q2015 to determine the safety, tolerability and efficacy in the destruction of Non-Muscle Invasive Bladder Cancer. In combination with transferrin, Theralase's lead PDC increases the efficacy that this technology has on the destruction of a wide range of cancers."
The 33,333 warrants of Matthew Perraton, are warrants from the 2013-11-11 17:22 ET - Private Placement.
http://www.stockwatch.com/News/Item.aspx?bid=Z-C:TLT-2120711&symbol=TLT®ion=C
These would expire on 2015-11-11, so he executed them around 1 month before the expiring.
Kristina Hachey also has some 166,667 of that PP. But I dont know, if she already executed them.
Hey 3bar, yes i'm using chrome. I found out, that the mobil versuon is workung for me, but in will give iexplorer a try ;), thanks for the hint.
Loool, 1. Feb feels bit like 11.March 2011 in japan
I like music :) and you popeljoe ;)
Sure, but the oversubscription shows, that there is still confidence and interests in niocorp
Premarket
Bid - Ask
1,5k at 0.68 - 8k at 0.68
NEWS
NioCorp Closes Convertible Note Financing
CENTENNIAL, COLORADO -- (Marketwired) -- 10/22/15 -- NioCorp Developments Ltd. ("NioCorp" or the "Company") (TSX: NB)(OTCQX: NIOBF)(FRANKFURT: BR3) announces that it has closed its non-brokered private placement of unsecured convertible promissory notes (the "Notes"), announced September 16, 2015, for gross proceeds of USD$800,000 (the "Private Placement"). The Private Placement was oversubscribed, and accordingly was increased from the previously announced maximum of USD$750,000 to USD$800,000.
The Notes will bear interest at a rate of 8%, payable quarterly in arrears, are non-transferable and have a term of three years from the date of issue. Principal under the Notes is repayable by the Company in cash or common shares of the Company at a conversion price of CAD$0.97 per common share, calculated on conversion or repayment using the then-current Bank of Canada noon exchange rate. Accrued but unpaid interest on the Notes will be payable by the Company in cash or common shares at a price per common share equal to the most recent closing price of the Company's common shares prior to the delivery to the Company of a request to convert interest, or the due date of interest, as applicable, calculated using the then-current Bank of Canada noon exchange rate. Repayment of any amount of interest by way of common share issuance will be subject to further Toronto Stock Exchange approval.
All securities issued under the Private Placement will be subject to a four-month hold period. The Company expects to use the proceeds of the Private Placement for general working capital purposes.
BID - ASK
1k at 0.67 - 6,5k at 0.67
Execution at 0.2 $
Does somebody know, if he hadn't executed the warrants, when would they expired
Sorry for my english, in germany, its called "Plusquamperfekt II" :)
Some big blocks. I hope management is not selling :P
Why is canadianinsider.com not working anylonger?
Cant have a look at TLT.
Some sales in germany. Around 60k shares after 20 min for 0.38 € which is about 0.56 CAD or 0.432 USD.
Lets see what the canadians and us guys think of the friday news.
I totally agree with you, but now its time to delivery.
If it is postponed again, it will get dirty.
I read comments like this the 4th or 5th time?!
Its time to deliver.
Thats a point i didnt get too.
because when I'm correct, they just have something like 500k - 750k $ in banks. With additional 750k from pp, we have nearly about 1250k - 1500k $ and if they continue to spend about 500k per month, we will only have enough money for 2.5 -3 month maximum
there could be done some good deals on the german exchange today.
somebody bought / sold 30k shares for 0,407 €, thats about 0,61 CAD or 0,456 USD.
bought some for 0,42 €, thats 0,63 CAD or 0,47 USD
Now its 2018 for production. Gesus help us
how much money did mark loses from the top?
Theralase applies to test anti-cancer treatment
2015-09-18 07:06 ET - News Release
Mr. Michael Borovec reports
THERALASE SUBMITS INVESTIGATIONAL TESTING AUTHORIZATION TO HEALTH CANADA FOR APPROVAL
Theralase Technologies Inc. has submitted an investigational testing authorization (ITA) for its anti-cancer technology to Health Canada for approval.
The ITA details information about the proprietary Theralase TLC-3200 oncology laser system, which Theralase plans to use to activate the company's lead photodynamic compound (PDC), TLD-1433, to destroy non-muscle invasive bladder cancer (NMIBC).
Pending approval of the following applications, Theralase plans to commence enrolling patients inflicted with NMIBC into a phase Ib clinical study at Princess Margaret Cancer Centre, University Health Network (UHN), to prove the primary objective of safety and tolerability, with an exploratory objective of efficacy:
Health Canada clinical trial application (CTA) (complete);
Health Canada ITA (complete);
UHN Research Ethics Board (REB).
Roger Dumoulin-White, president and chief executive officer, Theralase, stated: "The submission of an ITA to Health Canada for NMIBC is yet another advancement for the company in its quest to prove the safety, tolerability and efficacy of its anti-cancer technology in the destruction of NMIBC. Pending approval of the CTA, ITA and REB, UHN will commence enrolling and treating patients inflicted with this deadly disease."
We seek Safe Harbor.
thank you for your detailed opinion and insights
So 5-7 CAD seems not to be unrealistic, if all goes well
What is your opinion regarding the share price in 1-2 years when both TLC-2000 and the anticancer area are well established?
5-7 CAD?
Already 258k bid at 0.35 CAD
NEWS:
NioCorp Achieves Significant Metallurgical Milestone: First Production of Ferroniobium from the Elk Creek Resource
CENTENNIAL, COLORADO -- (Marketwired) -- 09/17/15 -- NioCorp Developments Ltd. ("NioCorp" or the "Company") (TSX: NB)(OTCQX: NIOBF)(FRANKFURT: BR3) is pleased to announce the production of ferroniobium using feed material from the Elk Creek Resource that meets specifications for commercial sale.
NioCorp has retained Kingston Process Metallurgy Inc. ("KPM") of Kingston, Ontario to conduct a series of pyrometallurgical tests to provide design information for the ferroniobium production process and to generate small quantities of ferroniobium. Testwork conducted in August of 2015 produced a final ferroniobium button that weighed 78 grams. The button was analyzed in KPM's internal laboratory, as well as at two external laboratories: SGS of Lakefield, Ontario and Actlabs of Ancaster, Ontario. NioCorp then compared the analytical results to a commercial specification for ferroniobium contained in the Company's offtake agreement with Thyssen Krupp Metallurgical Products GmbH and determined that the specification was met.
"We are extremely pleased with the work completed by the KPM team in order to achieve this important milestone for the Elk Creek project," said Mark A. Smith, Executive Chairman of NioCorp. "These results are the culmination of our efforts to demonstrate a complete flowsheet for the production of ferroniobium at a laboratory scale, and will be combined with the other elements of our metallurgical development program to advance our plant design to the feasibility level."
Qualified Persons:
Eric Larochelle, B.Eng of Roche Engineering Inc, a Qualified Person as defined by National Instrument 43-101, is responsible for the Elk Creek hydrometallurgical program and has read and approved the technical information contained in this news release.
Kevan Ford of Great Lakes Metallurgy Ltd., a Qualified Person as defined by National Instrument 43-101, is responsible for the Elk Creek pyrometallurgical program and has read and approved the technical information contained in this news release.
750k + remaining 500 - 700k in bank and a spend of around 500k per month could mean max 3 month till BFS, if not earlier. IMO
"Completion of detailed information regarding the device used to activate the drug"
Doesn't seems to be a big issue, doesn't it?
Hopefully CTA approval from HC is given fast.
Lot of good news in just a short period of time.
Hopefully market will recognize it and SP starts to grow
500 $ 01.01.2020 would be great!